INT MEDICAL (01501) announced that on May 11, 2026, and May 12, 2026, the company entered into share transfer agreements with the sellers to acquire a 23.18% equity interest in Valgen Holding Corporation for a total consideration of approximately $108 million. The target company holds a 100% stake in Dejin Medical. Valgen Holding Corporation is a holding company with no substantive business operations. Dejin Medical is primarily engaged in the research and development, production, and sales of interventional technologies and products for atrioventricular valve diseases, particularly in mitral and tricuspid valve interventions. Dejin Medical serves as the primary operating entity of the target group in China. Four self-developed products from the target group have been included in the National Medical Products Administration's special review program for innovative medical devices. These products are the MitralStitch® transapical mitral valve repair system, the DragonFly™ transcatheter mitral valve clamp system, the DragonFly-T® transcatheter tricuspid valve clamp system, and the DragonFire® transcatheter myocardial radiofrequency ablation system. Among them, the DragonFly™ transcatheter mitral valve clamp system is the first domestically produced transcatheter mitral valve product approved by the National Medical Products Administration. The board of directors believes that the acquisition provides the company with an opportunity to supplement its product pipeline in the structural heart disease field, achieve more comprehensive product coverage in this area, and enhance the group's overall competitiveness and long-term development potential in the cardiovascular interventional sector.